UNSPSC 51191502: Chlortalidone or chlorthalidone

This classification denotes a thiazide diuretic with the molecular formula C14H11ClN2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q0MQD1073Q, chemically known as 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1h-isoindol-1-yl)benzenesulfonamide but generally known as chlortalidone, which bears US NIH Compound Identifier 2732. European Medicines Agency schedules Chlortalidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06212MIG.

UNSPSC 51191502 Chlortalidone or chlorthalidone is a Commodity code representing pharmaceutical products procured by state and local health agencies, though recent state and local opportunities tagged under this code show minimal relevant activity. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities, indicating that state and local buyers source medications through cooperative purchasing vehicles and established wholesaler networks rather than direct vendor supply. The narrower pharmaceutical Commodity codes within this family typically support procurement of specific therapeutic agents by state health departments, Medicaid programs, state hospitals, correctional facilities, and municipal health clinics, with vendors required to maintain FDA compliance, current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, and substantial liability coverage.

The code shows activity in the upper Midwest, with MMCAP-coordinated procurement spanning Minnesota and Oregon as of the January 2026 RFP cycle. However, the single representative pharmaceutical opportunity on file (MMCAP's RFP S1070000015802, due March 26, 2026) does not specifically name chlortalidone or related diuretics in its disclosed scope—MMCAP's RFP was a broad generic-pharmaceutical aggregation seeking multiple therapeutic categories through authorized wholesalers rather than a targeted procurement for a single active pharmaceutical ingredient. The second tagged opportunity, the City of Meriden's IFB for sodium bisulfite (B027-15, due July 29, 2026), is a water-treatment chemical unrelated to pharmaceutical procurement. Recent opportunities specifically soliciting chlortalidone or similar antihypertensive diuretics are not present in the current state and local record. Firms pursuing this code should monitor cooperative purchasing vehicles managed by state procurement offices and state Medicaid agencies for broader pharmaceutical RFPs, as individual drug-specific solicitations are rare at the state and local level.